Prognostic factors of overall survival
| . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| Median OS . | P . | HR (95% CI) . | P . | |
| Age | .38 | |||
| > 70 y | 12.7 | |||
| ≤ 70 y | 15.0 | |||
| ECOG PS | < .0001 | < .0001 | ||
| 0-1 | 15.7 | 1 | ||
| ≥ 2 | 7.1 | 2.0 [1.4-2.9] | ||
| MDS type | .002 | |||
| Secondary | 9.2 | |||
| De novo | 15.3 | |||
| WHO diagnosis | .32 | |||
| RA/RARS/RCMD | 11.0 | |||
| RAEB1 | 13.1 | |||
| RAEB2 | 15.2 | |||
| AML (RAEB-t) | 9.7 | |||
| Interval from diagnosis | .05 | |||
| > 6 mo | 15.8 | |||
| ≤ 6 mo | 10.3 | |||
| Prior LD AraC | .75 | |||
| Yes | 14.9 | |||
| No | 13.1 | |||
| Prior ESA | .73 | |||
| Yes | 13.4 | |||
| No | 13.3 | |||
| Cytogenetic risk | < .0001 | < .0001 | ||
| Favorable | 22.4 | 1 | ||
| Intermediate | 15.0 | 1.4 [0.8-2.3] | .23 | |
| Unfavorable | 8.8 | 3.0 [2.0-4.3] | < .0001 | |
| IPSS risk | .004 | |||
| Intermediate-2 | 16.1 | |||
| High | 9.4 | |||
| Transfusion dependence | < .0001 | < .0001 | ||
| ≥ 4 RBC units/8 weeks | 10.3 | 1.9 [1.4-2.6] | ||
| 0-3 RBC units/8 weeks | 19.2 | 1 | ||
| ANC | .18 | |||
| ≥ 1.0 G/L | 12.0 | |||
| < 1.0 G/L | 15.1 | |||
| Platelets | .02 | |||
| ≥ 100 G/L | 19.6 | |||
| < 100 G/L | 12.3 | |||
| PB blasts | < .0001 | < .0001 | ||
| Present | 9.4 | 2.0 [1.5-2.7] | ||
| Absent | 19.8 | 1 | ||
| Bone marrow blasts | .11 | |||
| > 15% | 10.9 | |||
| ≤ 15% | 15.4 | |||
| . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| Median OS . | P . | HR (95% CI) . | P . | |
| Age | .38 | |||
| > 70 y | 12.7 | |||
| ≤ 70 y | 15.0 | |||
| ECOG PS | < .0001 | < .0001 | ||
| 0-1 | 15.7 | 1 | ||
| ≥ 2 | 7.1 | 2.0 [1.4-2.9] | ||
| MDS type | .002 | |||
| Secondary | 9.2 | |||
| De novo | 15.3 | |||
| WHO diagnosis | .32 | |||
| RA/RARS/RCMD | 11.0 | |||
| RAEB1 | 13.1 | |||
| RAEB2 | 15.2 | |||
| AML (RAEB-t) | 9.7 | |||
| Interval from diagnosis | .05 | |||
| > 6 mo | 15.8 | |||
| ≤ 6 mo | 10.3 | |||
| Prior LD AraC | .75 | |||
| Yes | 14.9 | |||
| No | 13.1 | |||
| Prior ESA | .73 | |||
| Yes | 13.4 | |||
| No | 13.3 | |||
| Cytogenetic risk | < .0001 | < .0001 | ||
| Favorable | 22.4 | 1 | ||
| Intermediate | 15.0 | 1.4 [0.8-2.3] | .23 | |
| Unfavorable | 8.8 | 3.0 [2.0-4.3] | < .0001 | |
| IPSS risk | .004 | |||
| Intermediate-2 | 16.1 | |||
| High | 9.4 | |||
| Transfusion dependence | < .0001 | < .0001 | ||
| ≥ 4 RBC units/8 weeks | 10.3 | 1.9 [1.4-2.6] | ||
| 0-3 RBC units/8 weeks | 19.2 | 1 | ||
| ANC | .18 | |||
| ≥ 1.0 G/L | 12.0 | |||
| < 1.0 G/L | 15.1 | |||
| Platelets | .02 | |||
| ≥ 100 G/L | 19.6 | |||
| < 100 G/L | 12.3 | |||
| PB blasts | < .0001 | < .0001 | ||
| Present | 9.4 | 2.0 [1.5-2.7] | ||
| Absent | 19.8 | 1 | ||
| Bone marrow blasts | .11 | |||
| > 15% | 10.9 | |||
| ≤ 15% | 15.4 | |||